Repetitive transcranial magnetic stimulation for treatment of elderly patients with depression – an open label trial

Gaby Abraham
Roumen Milev
Lauren Lazowski
Ruzica Jokic
Regina du Toit
Alan Lowe
Mood and Anxiety Program, Centre of Addiction and Mental Health
Department of Psychiatry, University of Toronto, Kingston, Ontario, Canada

Background: RTMS has been developed as a novel tool for treating depression but the clinical significance of this treatment has been variable, especially in the older depressed subjects.

Methods: Medication-resistant depressed patients 60 years or older were treated for two weeks (10 sessions) with high-frequency rTMS delivered to the left dorsolateral prefrontal cortex at 100% of motor threshold. Each session consisted of 20 trains at 10Hz delivered in 8-second duration. The patients continued taking their psychotropic medications throughout the study.

Results: Nineteen of the 20 subjects completed the trial. One subject dropped out after 8 sessions because of discomfort. The average age of our patients was 66.8 years (6 males and 14 females). Six patients responded and there was a 31.6% mean reduction in Hamilton Depression Rating Scale (HDRS) scores from baseline at the end of the treatment. There was statistically significant decrease from baseline in both HDRS and HARS scores at the end of treatment. rTMS was generally well tolerated.

Conclusion: These preliminary findings suggest that rTMS may be an effective treatment alternative to a subpopulation of medication resistant older depressed patients.

Keywords: transcranial magnetic stimulation, depressed elderly

Introduction
Major depression is a debilitating psychiatric disorder. Of all disability and premature loss of life in developing countries, depression accounts for 3.4% in women and 1.3% in men (Bland et al 1988; Bland 1996) and depression is the most common mental health problem in the elderly. Major depression is found in 1.7% of the elderly population, while pervasive depression is found in 13.4% of the elderly population (Baldwin and Simpson 1997).

Depression in the elderly has a considerable impact on their well-being and level of disability (Beekman et al 2002). Late-life depression may be due to a variety of factors including a longstanding vulnerability, severe stress, and vascular risk. However, depression in the elderly may be more difficult to treat than in other populations. Antidepressants can be administered as a first line treatment; however, this can be problematic, as older patients often cannot tolerate dosages high enough to produce an antidepressant response. Predicting the antidepressant effect and side-effects of pharmacological treatment in the elderly can also be difficult due to the variation in bioavailability. Increasing the duration of antidepressant treatment to up to 12 weeks in order to get a clinical response is also suggested for treatment of depression in the elderly population. However, this approach may be difficult, especially in cases of severe depression. Antidepressant class switching and augmentation with lithium is another treatment option. However, this can also be problematic due to intolerable side-effects or potential adverse reactions with non-psychotropic medications (Baldwin...
and Simpson 1997). Electroconvulsive therapy (ECT) is a treatment often used to treat depression in the elderly. Although ECT is quite effective and fast acting, it is associated with cognitive and other side-effects including nausea, headache and muscle aches (Datto 2000). In addition, due to the risks associated with anesthetic use in the elderly ECT is not always a viable option.

Repetitive transcranial magnetic stimulation (rTMS) may be another option in the treatment of late-life depression. Recently, two reviews of the evidence for the efficacy of rTMS as a treatment of depression were completed; they focused mainly on sham-controlled studies, literature reviews, and meta-analysis. These separate reviews indicate that there is statistical evidence that rTMS is more effective than sham treatment, despite the small degree of clinical improvement (Loo and Mitchell 2005; Rachid and Bertschy 2006). The review by Rachid and Bertschy (2006) also stated that rTMS treatment “is a relatively safe and well-tolerated technique with generally minor adverse effects such as localized scalp pain, headache and neck pain”.

There have only been a few studies examining the use of rTMS as an antidepressant treatment in elderly patients, for a brief review see Table 1. Figiel and colleagues (1998) treated a large group of adult patients and demonstrated that overall 42% of patients responded to rTMS. However, only 23% of the elderly patients in the study responded to treatment, suggesting increased efficacy of rTMS in younger populations as compared to elderly. The authors found the rTMS treatments to be well-tolerated in all patients. However, another recent study by Fabre et al (2004) on the effects of rTMS in vascular depression reported that 5 out of 11 patients showed a clinically meaningful improvement in Hamilton Depression Rating Scale scores (HDRS) (Hamilton 1960).

Another study (Mane et al 2001) found no significant change in HDRS (Hamilton 1960) scores before and after rTMS treatment in depressed elderly. They also reported 3 responders out of 10 subjects in the active treatment group and 3 responders out of 10 in the sham treatment group. These finding were attributed to insufficient stimulation parameters. Similarly, a more recent study of rTMS as add-on treatment for depression in the elderly reported no additional antidepressant effects of real stimulation versus sham treatment. It was also reported that treatment with rTMS was safe, as adverse events were rare and the cognitive assessment demonstrated no deterioration in cognitive function (Mosimann et al 2004).

In contrast to ECT, the benefits of rTMS include efficiency, cost-effective administration on an outpatient basis in contrast to ECT, no need for anesthesia, no seizure induction and a lack of significant cognitive side effects. rTMS may, therefore, be another viable option for the treatment of late-life depression. However, the lack of consensus regarding the antidepressant effects of rTMS in an elderly population indicate there is a need for further research in this area.

The aim of this study is to establish the efficacy and tolerance of repetitive transcranial magnetic stimulation (rTMS) for treatment of older patients with depressive disorders not responding to psychotropic medication.

### Materials and methods

#### Subjects

Patients were recruited from the population served by a specialized service for mood disorders (both in and out-patients were included). A local ethics board approved the study and only patients who were able to provide written informed consent were included.

Inclusion criteria were: DSM-IV (American Psychiatric Association, 2000) criteria for depressive disorder, unipolar or bipolar type with a HDRS score of ≥18; 60 years of age or older and willing and capable of continuing with the same

| Authors         | N  | Age range | Number of sessions | % MT | Hz | Response/outcome                      |
|-----------------|----|-----------|--------------------|------|----|---------------------------------------|
| Figiel 1998     | 50 | 22–89 (mean 60) | 5                  | 110  | 10 | 23% responded to Tx. Well-tolerated   |
| Manes 2001      | 20 | 60.7 ± 9.8 | 5                  | 80   | 20 | No significant change in HDRS scores with Tx |
| Mosimann 2004   | 24 | 62 ± 12   | 10                 | 100  | 20 | No antidepressant effects vs sham    |
| Fabre 2004      | 11 | 67.9 ± 6.7 | 10                 | 100  | 10 | 5 patients had clinically meaningful improvement in HDRS scores |
| Pradberg et al 1999 | 18 | 51.2 ± 16 | 5                  | 90   | 0.3 or 10 | 19% decline in HDRS score for slow rTMS and 6% decline for fast rTMS |
| Nahas et al 2004 | 18 | 61.2 ± 7.3 | 15                 | 114  | 5  | 35% decline over 3 weeks in HDRS score |
| Grunhaus et al 2000 | 20 | 58.4 ± 15.7 | 20                | 90   | 10 | 27% decline over 4 weeks in HDRS score |
medications through out the trial. Diagnosis was confirmed by experienced psychiatrists on the basis of an unstructured clinical interview using the DSM-IV checklist (American Psychiatric Association 2000).

Exclusion criteria included: Personal or family history of epilepsy or seizure disorder, mass brain lesion, metal in the skull or brain, history of a head trauma, patients who were actively suicidal, with a concurrent serious medical illness, history of alcohol or drug abuse in the last 3 months.

All patients had failed to respond to treatment with at least two adequate trials of at least 6-weeks duration, with an antidepressant. All patients were required to be on stable medications for 6 weeks prior to commencing in the study. They continued taking the maximum tolerated dose of the last antidepressant throughout the two weeks of treatment with rTMS and throughout follow-up. All other psychotropic medications were to remain unchanged for the same period unless readjustments were clinically indicated.

Outcome measures
1. Mood assessment was performed using the HDRS-21 item, Hamilton Anxiety Rating Scale (HARS) (Hamilton 1969) and the Beck Depression Inventory-II (BDI) (Beck et al 1961).
2. Visual Analogue Scale (VAS) for depression (-D), anxiety (-A) and physical discomfort (-PD).
3. The Clinical Global Impression (CGI) was completed as an additional scale in monitoring response to treatment.
4. The Mini-Mental Status Exam (MMSE) (Folstein et al 1975).

The outcome measures (HDRS, HARS, BDI, MMSE, and CGI) were administered at baseline (before rTMS treatment), mid-treatment (after 5 treatments), at the end of treatment (after 10 treatments), two weeks and 1 month after the completion of rTMS. The VAS-D, VAS-A, and VAS-PD were administered after each rTMS session, two weeks and 1 month after the completion of rTMS treatment.

Results
Twenty patients were enrolled in the study, of these 19 patients completed all 10 rTMS treatments. One patient completed 8 of the 10 treatments but was unable to continue due to local discomfort and headache. Several of the remaining patients developed slight transient discomfort with the first treatment, but none had severe or persistent pain. Of the 20 patients, 6 (30%) were male and 14 (70%) were female, 3 (15%) suffered from bipolar depression and 17 (85%) suffered from unipolar depression. The average age was 66.8 (±6.4) years and ranged from 60–80 years old. Fifteen patients were assessed at the 2-week follow-up and thirteen were assessed at the 1-month follow-up visit.

There was a significant decrease in the mean HDRS score for the entire population from baseline 25.3 SD 5.8 to 17.3 SD 6.5 after 10 treatments, p = 0.0003. There was a 31.6% mean reduction in HDRS from baseline. The mean HDRS score 1 month after the completion of treatment was found to be 16.6 (SD 8.7), a 34.3% mean reduction from baseline (Table 2).

After 10 treatments 6 patients showed a reduction in HDRS scores of at least 50% and another patient showed a reduction of at least 50% at the 1-month follow-up visit. Two of the 6 patients also reached remission (defined as a HDRS score <8). The patient who showed the reduction of 50% at the 1 month follow up visit also reached remission at the 1 month follow up visit.

The mean HARS score at baseline was 19.3 (±8.2) and it reduced to 13.2 (±10.1) after 10 treatments. This is a 31.6% mean reduction from baseline. The mean HARS score 1 month after the completion of treatment was found to be 13.7 (±7.5), a 29.0% mean reduction from baseline (Figure 1).

Both HDRS and HARS scores showed a significant decrease at the end of treatment (visit 10) from baseline (p = 0.0003 and p = 0.03, respectively). As shown in Table 2, both the BDI and the CGI decreased significantly at the end of treatment from baseline (p = 0.0396 and p = 0.0088, respectively). The VAS for depression and anxiety did not show a significant change (p = 0.117 and p = 0.053, respectively) with treatment. The VAS for physical discomfort did not show a significant increase from baseline to the end of treatment (p = 0.336). Also the MMSE did not show a significant change from baseline to the end of treatment (p = 0.586).

Discussion
This study assessed the effect of rTMS applied to the left dorsal prefrontal cortex as an add-on treatment in...
medication-resistant depressed patients who were 60 years of age or older. After two weeks (10 rTMS treatments), 30% (6 out of 20 patients) met response criteria (>50% improvement in HDRS), with two of these patients also meeting criteria for remission (HDRS ≤ 8).

This finding compares favorably with that of Nahas and colleagues (2004) who used distance adjusted TMS treatments in patients 65–75 years of age. In their study rTMS was administered for 3 weeks to the DLPFC using a stimulation intensity of 114% of the motor threshold (MT) as compared to 2 weeks at 100% of MT in our study. In Nahas et al 28% (5 of 18 subjects) met criteria for response; four of these five patients had exit HDRS scores ≤ 8, and thus met criteria for remission. Although, our results show a higher number of responders to rTMS, Nahas’s study reported a higher number of remitters. The results of our study demonstrate a 31.6% mean reduction in HDRS scores from baseline to the end of study, increasing to 34.3% at one month follow up. Similarly, Nahas et al reported a 35.2% drop on the 28-item HDRS from baseline. Finally, the same authors reported that 10 out of 18 subjects were very much improved or much improved according to the CGI. In our study, CGI demonstrated much or very much improvement in six patients.

Mosimann et al (2004) treated elderly depressed patients (mean age = 62 years) with 10 daily rTMS treatments at 100% of motor threshold, similar to our stimulation parameters, and reported a 20% reduction in HDRS-21 scores in the active treatment group. Interestingly, the sham treated group showed a 17% reduction in HDRS. In the Mosimann study, 26.6% (4 of 24) of patients receiving real TMS were responders, similar to the results of our study.

Previous studies found no deterioration in cognitive function in rTMS-treated subjects (Martis et al 2003; Speer et al 2001). In our study there was no evidence of cognitive deterioration, as MMSE scores remained unchanged throughout the study. However, more rigorous cognitive

| BDI | Baseline | 25.0 ± 13.3 | 24.2 ± 13.6 |
|-----|----------|-------------|-------------|
| Depression | 64.5 ± 23.3 | 52.2 ± 28.9 | 55.5 ± 38.5 |
| Anxiety | 66.3 ± 25.6 | 48.7 ± 29.5 | 40.8 ± 39.2 |
| Physical discomfort | 24.6 ± 25.8 | 20.8 ± 26.4 | 36.4 ± 31.7 |
| CGI | 4.7 ± 0.7 | 3.9 ± 1.1 | 3.1 ± 1.3 |
| MMSE | 28.2 ± 2.3 | 29.1 ± 1.5 | 28.8 ± 1.7 |

Values presented as mean ± SD.

**Significant decrease from baseline.
tests are needed to confirm the absence of deterioration in cognitive functioning.

Mosimann et al (2004) found rTMS to be a safe treatment with none of the patients withdrawing from the study or reporting serious adverse effects. One patient in our study withdrew, after 8 sessions, because of discomfort and headaches.

This is similar to the study by Su et al (2005) where 3 out of 30 patients dropped out of the treatment because of pain or worsening of clinical symptoms. As well, four patients in the active and two patients in the sham group reported headaches, which is consistent with complaints reported by our study subjects.

The response rate obtained by most other studies are quite similar to our data, although in contrast to Su et al (2005) who found no responder in patients older than 55 years of age. In our study we did not find any significant difference in age, sex, or degree of cognitive impairment between responders and non-responders. In addition, responders and non-responders did not differ in severity of depression, as measured by initial HDRS scores or number of previous antidepressant treatments.

It has yet to be established if rTMS’s antidepressant response rates differ between elderly and younger populations of patients with depression. Published reports indicate a lower antidepressant effect of rTMS in elderly depressed patients as compared to younger populations (Figiel et al 1998; Pradberg et al 1999; Su et al 2005). Fregni et al (2006) found age and treatment refractoriness to be significant negative predictors of depression improvement. They reported that TMS antidepressant therapy in younger and less treatment resistant patients resulted in better outcomes. The findings in our study of a response rate of 31.6% after only 10 daily sessions of rTMS at 100% of MT is comparable to the response rates of 30% and 35% respectively reported by Garcia-TORO et al (2001) and Fitzgerald et al (2003) in younger adults.

Two more recent studies reported similar response rates after treating younger adults at higher intensities and for longer sessions. Response rate of 30% was reported by Isenberg et al (2005) who gave 4 weeks of high frequency rTMS; and Avery et al (2006) found a 32% response rate when rTMS was administered for 15 sessions at an intensity of 110% of MT. Although, we administered rTMS for 10 sessions at an intensity of 100% MT, it appears that our older patients responded well.

Rossini et al (2005), who reported a response rate of 61%, argued that treatment response was unrelated to the demographic and clinical characteristics of their patients. Fitzgerald et al (2006) have also reported no relationship between age and response to rTMS treatment. In addition, it is of interest to note that Jorge et al (2004) reported that reduction of depression symptoms in rTMS treated post stroke patients was not influenced by the patient’s age or type or location of ischemic strokes.

The limitations of this study require some consideration. This is non-controlled, open study with a small sample size. This is a significant limitation, which likely restricted the statistical power. Our patients all received antidepressants during the trial. We ensured that all patients stayed on a stable dose of the current medications for at least six weeks before commencement of rTMS, during the trial and follow-up period. However, changes to psychotropic medications (excluding antidepressants) were allowed, throughout the study, where clinically indicated. Since the study lacks a control group we cannot exclude the possibility of a placebo effect. The response to rTMS seen in our study may be due to a placebo effect of a cutting edge treatment, but given that all of our subjects had been taking stable doses of the same medication for at least six weeks, were not improving before the trial and had a high degree of resistance, this is unlikely. Khan et al (2002) reported that more severely depressed patients responded poorly to placebo compared to antidepressant treated subjects.

Recently, it has been suggested that 10 treatments and 100% of MT may not be sufficient to produce a maximum response. But our study was planned and started a few years ago when routine rTMS treatment was a course given for two weeks. Thus, administration of a fixed number (10) of rTMS sessions may have reduced the efficacy of our treatment as a higher number of sessions optimized the clinical benefit of treatment as demonstrated in some recent studies (Janicak et al 2002; Grunhaus et al 2003; Rossini et al 2005). However the literature is lacking a study that directly compares the effects of 2 different numbers of pulses per day on mood. More rTMS sessions even at higher stimulation intensity have not consistently produced better clinical outcome as reported in newer studies (Isenberg et al 2005; Avery et al 2006). Rossini et al (2005) suggested that methodological factors might be responsible for the variable results reported in the literature.

In conclusion, rTMS is a safe and well-tolerated treatment and may be a useful adjunctive treatment to medications in elderly treatment resistant depressed patients. We believe our findings add to the growing body of literature that suggests the effectiveness of rTMS. Despite the fact that
the generalizability of our study findings are limited, rTMS treatment in older depressed population is showing encouraging results and requires further study.

References

American Psychiatric Association. 2000. Diagnostic and statistical manual for mental disorders (DSM-IV-TR), 4th Ed Text Revision edn. Washington, DC.

Avery DH, Holtzheimer PE 3rd, Fawaz W, et al. 2006. A controlled study of repetitive transcranial magnetic stimulation in medication-resistant major depression. *Biol Psychiatry*, 59:187–94.

Baldwin RC, Simpson S. 1997. Treatment resistant depression in the elderly: a review of its conceptualization, management and relationship to organic brain disease. *J Affect Disord*, 46:163–73.

Beck AT, Ward CH, Mendelsohn M, et al. 1961. An inventory for measuring depression. *Arch Gen Psychiatry*, 4:561–71.

Beekeman ATF, Penninx BWJH, Deeg DJH, et al. 2002. The impact of depression on the well-being, disability and use of services in older adults: a longitudinal perspective. *Acta Psychiatr Scand*, 105:20–7.

Bland RC, Newman SC, Orn H. 1988. Epidemiology of psychiatric disorders in Edmonton. *Acta Psychiatr Scand*, 77:S388.

Bland RC. 1996. International health and psychiatry. *Can J Psychiatry*, 41:11–15.

Datto CJ. 2000. Side effects of electroconvulsive therapy. *Depress Anxiety*, 12:130–4.

Fabire I, Galinowski A, Oppenheim C, et al. 2004. Antidepressant efficacy and cognitive effects of repetitive transcranial magnetic stimulation in vascular depression: an open label trial. *Int J Geriatr Psychiatry*, 19:833–42.

Figsel GS, Epstein C, MacDonald WM, et al. 1998. The use of rapid-rate transcranial magnetic stimulation (rTMS) in refractory depressed patients. *J Neuropsychiatry*, 10:20–5.

Fitzgerald PB, Brown TL, Marston NA, et al. 2003. Transcranial magnetic stimulation in the treatment of depression: a double blind, placebo-controlled trial. *Arch Gen Psychiatry*, 60:1002–8.

Fitzgerald PB, Huntsman S, et al. 2006. A randomized trial of low-frequency right-prefrontal-cortex transcranial magnetic stimulation as augmentation in treatment-resistant major depression. *Int J Clin Neuropsychopharm*, 9:655–66.

Folstein MF, Folstein SE, McHugh PR. 1975. Mini-mental state: A practical method for grading the state of patients for the clinician. *Psychiatric Research*, 12:189–98.

Fregni F, Marcolin MA, Myczkowski M, et al. 2006. Predictors of antidepressant response in clinical trials of transcranial magnetic stimulation. *Int J Neuropsychopharmacol*, 9:641–54.

Garcia-Toro M, Mayol A, Amillas H, et al. 2001. Modest adjunctive benefit with transcranial magnetic stimulation in medication-resistant depression. *J Affect Disord*, 64:271–5.

Grunhaus L, Dannon PN, Schreiber S, et al. 2000. Repetitive transcranial magnetic stimulation is as effective as electroconvulsive therapy in the treatment of nondelusional major depressive disorder: an open study. *Biol Psychiatry*, 47:314–24.

Grunhaus L, Schreiber S, Dolberg OT, et al. 2003. A randomized controlled comparison of electroconvulsive therapy and repetitive transcranial magnetic stimulation in severe and resistant nonpsychotic major depression. *Biol Psychiatry*, 23:56–62.

Grunhaus L, Schreiber S, Dolberg OT, et al. 2000. Repetitive transcranial magnetic stimulation in the treatment of depressed patients. *Arch Gen Psychiatry*, 57:135–46.

Hamilton M. 1960. A rating scale for depression. *J Neurosurg Psychiatry*, 23:56–62.

Hamilton M. 1969. A rating scale for anxiety. *Br J Psychiatry*, Special Publication:76–9.

Isenberg K, Downs D, Pierce K, et al. 2005. Low frequency rTMS stimulation of the right frontal cortex is as effective as high frequency rTMS stimulation of the left frontal cortex for antidepressant free, treatment-resistant depressed patients. *Ann Clin Psychiatry*, 17:153–9.

Janicak PG, Dowd SM, Martis B, et al. 2002. Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for major depression: preliminary results of a randomized trial. *Biol Psychiatry*, 51:659–67.

Jorge RE, Robinson RG, Tateno A, et al. 2004. Repetitive transcranial magnetic stimulation as treatment of post stroke depression: a preliminary study. *Biol Psychiatry*, 55:398–05.

Khan A, Leventhal RM, Khan SR, et al. 2002. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. *J Clin Psychopharmacol*, 22:40–5.

Loo CK, Mitchell PB. 2005. A review of the efficacy of transcranial magnetic stimulation (TMS) treatment for depression, and current and future strategies to optimize efficacy. *J Affect Disord*, 88:255–67.

Manes F, Jorge R, Morcuende M, et al. 2001. A controlled study of repetitive transcranial magnetic stimulation as a treatment of depression in the elderly. *Int Psychogeriatr*, 13:225–31.

Martis B, Alam D, Dowd SM, et al. 2003. Neurocognitive effects of repetitive transcranial magnetic stimulation in severe major depression. *Clin Neurophysiol*, 114:1125–32.

Mosimann UP, Schmitt W, Greenberg BD, et al. 2004. Repetitive transcranial magnetic stimulation: a putative add-on treatment for major depression in elderly patients. *Psychiatry Res*, 126:123–33.

Nahas Z, Xingbao L, Kozel A, et al. 2004. Safety and benefits of distance-adjusted prefrontal transcranial magnetic stimulation in depressed patients 55–75 years of age: a pilot study. *Depression Anxiety*, 19:249–56.

Pradberg F, Zwanzer P, Thomas H, et al. 1999. Repetitive transcranial magnetic stimulation in pharmacology-refractory major depression: comparative study of fast and slow and sham rTMS. *Psychiatry Research*, 88:163–71.

Rachid F, Bertschy G. 2006. Safety and efficacy of repetitive transcranial magnetic stimulation in the treatment of depression: a critical appraisal of the last 10 years. *Neurophysiol Clin*, 36:157–83.

Rossini D, Luca A, Zanardi R, et al. 2005. Transcranial magnetic stimulation in treatment-resistant depressed patients: a double blind, placebo-controlled trial. *Psychiatry Research*, 137:1–10.

Speer AM, Repella JD, Figueras S, et al. 2001. Lack of adverse cognitive effects of 1 Hz and 20 Hz repetitive transcranial magnetic stimulation at 100% of motor threshold over the left prefrontal cortex in depression. *Electroconvulsive Therapy*, 17:259–63.

Su TP, Huang CC, Wei IH. 2005. Add-On rTMS for Medication-Resistant Depression: a randomized, double blind, sham-controlled trial in Chinese patients. *J Clin Psychiatry*, 66:930–7.